• Total revenue up 22.3% to $53.1 million
• Clinical Trials revenue grew 28.2% to $50.6 million
• Profit before tax increased 95.8% to $13.9 million

Cogstate Ltd has reported its financial results for the year ended 30 June 2025, with the company delivering strong growth across key metrics. Total revenue increased 22.3% to $53.1 million, driven by a 28.2% rise in Clinical Trials revenue to $50.6 million. The Healthcare segment revenue declined 37.1% to $2.5 million. Profit before income tax grew 95.8% to $13.9 million, with the first half of the year contributing $5.2 million and the second half $8.7 million. Net profit after tax increased 86.1% to $10.1 million. The company had $76.3 million of contracted Clinical Trials revenue at 30 June 2025, down from $85.6 million a year earlier, but new contracts signed during the year increased 53% to $41.3 million. Contracted Healthcare revenue from Eisai also declined over the year. Total contracted future revenue decreased 11% to $90.0 million as at 30 June 2025. The company's headcount decreased slightly to 159.1 full-time equivalent employees at the end of the financial year.